News Louis Lehot Speaks on 2024 Venture Capital Trends at the FOA Global Impact Forum Foley & Lardner LLP partner Louis Lehot moderated a panel on February 29, 2024, at…Louis LehotMarch 1, 2024
News Foley Represents TCGX as Lead Investor in $127.5M Private Placement for Adverum Biotechnologies Foley & Larder LLP represented TCG Crossover (“TCGX”) as the lead investor in the $127.5…Louis LehotFebruary 13, 2024
News Foley Represents TCGX as Investor in $120M Private Placement for Silence Therapeutics Foley & Larder LLP represented TCG Crossover (“TCGX”) as an investor in the $120 million…Louis LehotFebruary 13, 2024
News Foley Represents TCGX as Lead Investor in $120M Private Financing for Mineralys Therapeutics Foley & Larder LLP recently represented TCG Crossover (“TCGX”) as a lead investor in the…Louis LehotFebruary 13, 2024
News Foley Represents TCGX as Investor in Tourmaline Bio, Concurrent with Merger with Talaris Therapeutics Foley & Lardner LLP represented TCGX as an investor in the $75 million private placement…Louis LehotJanuary 24, 2024
News Foley Represents TCGX as Co-Lead Investor in $150M Series B Financing for Alkeus Pharmaceuticals Foley & Lardner LLP represented TCGX as co-lead investor in the $150 million Series B…Louis LehotJanuary 23, 2024
News Foley Represents NEA as Lead Investor in Comanche Biopharma Series B Round Foley & Lardner LLP recently represented New Enterprise Associates, Inc. (NEA) as lead investor in…Louis LehotJanuary 18, 2024
News Foley Serves as Legal Adviser to knownwell in $20M Series A Funding Foley & Lardner LLP served as legal adviser to knownwell, an in-person and virtual weight-inclusive…Von BryantDecember 21, 2023
Blogs AI in Health Care: Powering Patient Outcomes With the Health Care & Life Sciences sector under pressure to improve patient outcomes while…Foley IgniteDecember 11, 2023
Blogs 2024 Predictions: Unveiling the future of healthcare mergers and acquisitions This originally appeared in MobiHealthNews on December 8, 2023. Reprinted with permission. Today, a tale of two…Nate LacktmanDecember 8, 2023